Chs-828
| Title | Journal |
|---|---|
| Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase. | Toxicological sciences : an official journal of the Society of Toxicology 20150301 |
| Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner. | The Journal of biological chemistry 20120622 |
| Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells. | The Journal of pharmacology and experimental therapeutics 20110901 |
| Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data. | Cancer chemotherapy and pharmacology 20100501 |
| Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase. | BMC cancer 20100101 |
| Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. | Anti-cancer drugs 20090601 |
| Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments. | Journal of translational medicine 20090101 |
| Anticancer agent CHS-828 inhibits cellular synthesis of NAD. | Biochemical and biophysical research communications 20080321 |
| Ariad Pharmaceuticals wins first round over Eli Lilly, patents on methods can be far-reaching. | Journal of the National Cancer Institute 20060802 |
| CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome. | Anticancer research 20060101 |
| EB1627: a soluble prodrug of the potent anticancer cyanoguanidine CHS828. | Bioorganic & medicinal chemistry letters 20050516 |
| Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20050501 |
| Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. | European journal of cancer (Oxford, England : 1990) 20050301 |
| Antitumoural effects of the pyridyl cyanoguanidine CHS 828 on three different types of neuroendocrine tumours xenografted to nude mice. | Neuroendocrinology 20050101 |
| Anticancer agent CHS 828 suppresses nuclear factor-kappa B activity in cancer cells through downregulation of IKK activity. | International journal of cancer 20040820 |
| Multiparametric evaluation of apoptosis: effects of standard cytotoxic agents and the cyanoguanidine CHS 828. | Molecular cancer therapeutics 20040501 |
| Synthesis and in vitro cytotoxicity of 5-substituted 2-cyanoimino-4-imidazodinone and 2-cyanoimino-4-pyrimidinone derivatives. | Bioorganic & medicinal chemistry letters 20040308 |
| Development and characterization of two human tumor sublines expressing high-grade resistance to the cyanoguanidine CHS 828. | Anti-cancer drugs 20040101 |
| Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines. | Anti-cancer drugs 20040101 |
| Segmental analysis of molecular surface electrostatic potentials: application to enzyme inhibition. | Journal of molecular modeling 20030401 |
| Activation of p53 protein in normal and in tumor cells by a novel anticancer agent CHS 828. | Drugs under experimental and clinical research 20030101 |
| The combination of the antitumoural pyridyl cyanoguanidine CHS 828 and etoposide in vitro--from cytotoxic synergy to complete inhibition of apoptosis. | British journal of pharmacology 20021001 |
| Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patients. | Chemotherapy 20020901 |
| A Phase I study of CHS 828 in patients with solid tumor malignancy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20020901 |
| Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1. | Cancer research 20020801 |
| In vitro activity of the novel cytotoxic agent CHS 828 in childhood acute leukemia. | Anti-cancer drugs 20020801 |
| CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs. | Pediatric research 20020501 |
| Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells. | Biochemical pharmacology 20020415 |
| Metabolic effects of the cytotoxic guanidino-containing drug CHS 828 in human U-937 lymphoma cells. | Anticancer research 20020101 |
| Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action. | The Journal of pharmacology and experimental therapeutics 20011201 |
| Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro. | Anti-cancer drugs 20011101 |
| Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology. | Biochemical pharmacology 20010515 |
| Cellular pharmacodynamics of the cytotoxic guanidino-containing drug CHS 828. Comparison with methylglyoxal-bis(guanylhydrazone). | European journal of pharmacology 20010420 |
| Cell death with atypical features induced by the novel antitumoral drug CHS 828, in human U-937 GTB cells. | European journal of pharmacology 20010413 |
| In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients. | Cancer letters 20010126 |
| Temporal effects of the novel antitumour pyridyl cyanoguanidine (CHS 828) on human lymphoma cells. | European journal of cancer (Oxford, England : 1990) 20010101 |
| A hollow fiber model for in vitro studies of cytotoxic compounds: activity of the cyanoguanidine CHS 828. | Anti-cancer drugs 20010101 |
| Rapid screening of Veillonella by ultraviolet fluorescence. | Journal of clinical microbiology 19751201 |